Form 4: Aurinia Pharmaceuticals EVP Volker Knappertz Sells 4,930 Shares
SEC Form 4 Filing
Volker Knappertz, EVP of Research and Development at Aurinia Pharmaceuticals, sold 4,930 shares of common stock on February 27, 2024.
Summary
- On February 27, 2024, Volker Knappertz, the EVP of Research and Development at Aurinia Pharmaceuticals Inc., sold 4,930 shares of the company's common stock.
- The sale was executed at a price of $6.1 per share.
- Following the transaction, Knappertz directly owns 319,128 shares of Aurinia Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: This is a neutral event. An executive selling shares doesn't necessarily indicate a negative outlook, but it's information investors should be aware of.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading by corporate insiders.
Stakeholder Impact
- Shareholders may interpret the stock sale as a signal, although it could be for personal financial reasons.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of the stock sale transaction. |
| 02/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.